Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Recap – Editas Medicine Advances Crispr Therapy

Crispr genome edits illustration

(NIH.gov)

2 Dec. 2018. While much the world watched, and disapproved of, a Chinese researcher editing the genomes of embryos leading to the birth of twins, Editas Medicine in Cambridge, Massachusetts received the go-ahead to conduct a clinical trial using the genome editing technique Crispr. On Friday, the Food and Drug Administration, in an approved investigational new drug application, authorized Editas to test Crispr as a treatment for a rare inherited eye disease known as Leber congenital amaurosis type 10.

Here’s what else we reported on last week:

*     *     *

Please share Science & Enterprise ...

Comments are closed.